Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$145.90

-1.34 (-0.91%)

05:28
01/12/17
01/12
05:28
01/12/17
05:28

TESARO receives CRL from FDA for rolapitant IV NDA

TESARO announced that the FDA has issued a Complete Response Letter, or CRL, regarding the rolapitant IV New Drug Application, or NDA, for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. FDA requested additional information regarding the in vitro method utilized to demonstrate comparability of drug product produced at the two proposed commercial manufacturers for rolapitant IV that were included in the NDA. TESARO is working expeditiously to provide the requested information. The CRL did not identify concerns related to the safety or efficacy of rolapitant IV or request additional clinical studies. No concerns were raised regarding the active pharmaceutical ingredient, which is also used for the Varub oral product. TESARO identified potential deficiencies at the original contract manufacturer for rolapitant IV drug product, secured a second drug product supplier and included data from this manufacturer in the NDA. During the NDA review, FDA requested and TESARO provided in vitro data to demonstrate comparability of drug product made at the two manufacturing sites.

  • 30

    Jun

TSRO Tesaro
$145.90

-1.34 (-0.91%)

12/27/16
FBRC
12/27/16
NO CHANGE
Target $151
FBRC
Outperform
FBR Capital ups TESARO price target to $151
FBR Capital analyst Ed White raised his price target for TESARO to $151 from $133 and keeps the Outperform rating on the shares. The oncology-focused biopharmaceutical company closed Friday up $7.27 to $139.86. TESARO recently announced that the FDA has granted Priority Review for niraparib with a June 30, 2017 action date, White tells investors in a research note. He believes niraparib could be a potential blockbuster PARP inhibitor. Meanwhile, the launch of Varubi continues to "ramp up," with sequential quarter-over-quarter unit growth of 14%, the analyst writes. White says the drug achieved a 28% share of the oral NK-1 market in the U.S. in September.
01/04/17
GABE
01/04/17
NO CHANGE
GABE
Gabelli sees Incyte as more likely target following Gilead hire
Gilead (GILD) is more likely to buy Incyte (INCY) after naming Alessandro Riva to head its Hematology and Oncology Therapeutic unit, Gabelli analyst Jing He tells investors in a research note. Dr. Riva is a Novartis (NVS) veteran while Incyte is led by a team of Novartis veterans and has collaborated with Novartis Oncology on its key drug, Jakafi, the analyst points out. He believes Incyte is "big enough to move the needle" and bring long term growth to Gilead. The analyst lists Seattle Genetics (SGEN) and TESARO (TSRO) as other potential targets for the biotech giant. He believes Incyte is the "best fit."
01/09/17
LEER
01/09/17
NO CHANGE
Target $152
LEER
Outperform
TESARO price target raised to $152 from $115 at Leerink
Leerink analyst Seamus Fernandez raised his price target for TESARO to $152 from $115 to fully incorporate his high expectations for a broad label and reflect niraparib's transformation to a commercial stage asset. The analyst notes that the "strong data" from niraparib's NOVA trial, along with the lack of an expected FDA panel, should result in a broad label in the second-line or greater ovarian cancer maintenance setting, while ongoing niraparib trials in breast cancer and front-line ovarian cancer maintenance and the company's IO platform should be additional potential drivers of upside for the stock. Fernandez sees TESARO as an "attractive takeout target," and reiterates an Outperform rating on the shares.
01/10/17
LEER
01/10/17
NO CHANGE
LEER
Outperform
ARIAD acquisition supports potential takeout premium for TESARO, says Leerink
Leerink analyst Seamus Fernandez says the acquisition of ARIAD (ARIA) by Takeda (TKPYY) for $24 per share appears to be relatively in-line with other commercial stage acquisitions, and supports a potential acquisition price for TESARO (TSRO) of greater than $170 per share based on consensus forecasts. While TESARO remains well positioned to grow independently, the analyst believes a validated PARP inhibitor like niraparib could offer a durable and strategically important product opportunity for multiple suitors. He reiterates an Outperform rating on TESARO's shares.

TODAY'S FREE FLY STORIES

DIS

Disney

$115.29

1.59 (1.40%)

14:19
04/25/17
04/25
14:19
04/25/17
14:19
Periodicals
Disney targets Star Wars, Frozen sequels for 2019, Deadline reports »

Disney has unveiled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
04/25/17
04/25
14:17
04/25/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
04/25/17
04/25
14:16
04/25/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBB

Hubbell

$117.83

-3.7 (-3.04%)

14:14
04/25/17
04/25
14:14
04/25/17
14:14
Hot Stocks
Hubbell acquires connected home products maker iDevices »

iDevices announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 09

    May

  • 09

    May

  • 09

    May

TWTR

Twitter

$14.80

0.085 (0.58%)

14:13
04/25/17
04/25
14:13
04/25/17
14:13
Technical Analysis
Twitter technical comments before earnings »

Ahead of earnings news,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CL

Colgate-Palmolive

$74.15

0.49 (0.67%)

14:11
04/25/17
04/25
14:11
04/25/17
14:11
Options
Colgate attracts a call writer ahead of earnings »

Colgate attracts a call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 31

    May

SQ

Square

$18.11

0.26 (1.46%)

14:06
04/25/17
04/25
14:06
04/25/17
14:06
Options
Square call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 16

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

14:05
04/25/17
04/25
14:05
04/25/17
14:05
General news
NY Fed's overnight reverse repo totaled $117.0 B, with 45 counterparties »

NY Fed's overnight…

STX

Seagate

$49.42

1.16 (2.40%)

, WDC

Western Digital

$85.77

2.66 (3.20%)

14:00
04/25/17
04/25
14:00
04/25/17
14:00
Earnings
On The Fly: What to watch in data storage earnings reports »

Companies in the data…

STX

Seagate

$49.42

1.16 (2.40%)

WDC

Western Digital

$85.77

2.66 (3.20%)

MU

Micron

$26.57

-0.75 (-2.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 31

    May

  • 07

    Jun

  • 08

    Jun

14:00
04/25/17
04/25
14:00
04/25/17
14:00
General news
Stocks drifting at session highs in afternoon trading »

Stocks have been sharply…

MTBC

Medical Transcription Billing

$0.42

-0.03 (-6.67%)

13:57
04/25/17
04/25
13:57
04/25/17
13:57
Hot Stocks
Medical Transcription Billing partners with Health Compliance Network »

MTBC announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$8.89

0.18 (2.07%)

13:54
04/25/17
04/25
13:54
04/25/17
13:54
Hot Stocks
Sprint promotion adds free fifth line to unlimited offer »

Sprint announced that for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

CMA

Comerica

$70.14

0.03 (0.04%)

13:53
04/25/17
04/25
13:53
04/25/17
13:53
Hot Stocks
Comerica raises quarterly dividend 13% to 26c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WFC

Wells Fargo

$54.57

0.92 (1.71%)

13:51
04/25/17
04/25
13:51
04/25/17
13:51
Hot Stocks
Wells Fargo chairman: Stockholders sent board 'clear message of dissatisfaction' »

Commenting on the results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

D

Dominion

$77.54

-0.53 (-0.68%)

13:51
04/25/17
04/25
13:51
04/25/17
13:51
Options
Downside put buyers in Dominion Resources ahead of earnings »

Downside put buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 10

    May

  • 21

    May

WFC

Wells Fargo

$54.59

0.935 (1.74%)

13:50
04/25/17
04/25
13:50
04/25/17
13:50
Hot Stocks
Wells Fargo confirms all directors reelected, says votes dip as low as 53% »

Wells Fargo announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

PG

Procter & Gamble

$89.97

0.415 (0.46%)

13:48
04/25/17
04/25
13:48
04/25/17
13:48
Technical Analysis
Procter & Gamble technical comments before earnings »

Ahead of earnings news,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

XLNX

Xilinx

$60.65

2.96 (5.13%)

13:46
04/25/17
04/25
13:46
04/25/17
13:46
Options
Xilinx call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVHY

Vivendi

$20.34

1.39 (7.34%)

13:45
04/25/17
04/25
13:45
04/25/17
13:45
Periodicals
Vivendi's UMG valued at $22B by banks seeking float, Reuters says »

Bankers aiming to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTHIY

Hitachi

$53.93

0.09 (0.17%)

, KKR

KKR

$17.51

0.25 (1.45%)

13:45
04/25/17
04/25
13:45
04/25/17
13:45
Periodicals
Hitachi plans to sell chipmaking device unit to KKR, JIP, Nikkei reports »

Hitachi (HTHIY) is…

HTHIY

Hitachi

$53.93

0.09 (0.17%)

KKR

KKR

$17.51

0.25 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

CLRO

ClearOne

$10.00

0.1 (1.01%)

13:43
04/25/17
04/25
13:43
04/25/17
13:43
Hot Stocks
ClearOne says awarded patent on 'beamforming' echo cancellation »

ClearOne announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FFIN

First Financial

$40.30

0.7 (1.77%)

13:36
04/25/17
04/25
13:36
04/25/17
13:36
Hot Stocks
First Financial raises quarterly dividend 5.6% to 19c per share »

The board of First…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

FNHC

Federated National

13:35
04/25/17
04/25
13:35
04/25/17
13:35
Hot Stocks
Breaking Hot Stocks news story on Federated National »

Lenox raises passive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

CAG

Conagra Brands

$39.48

-1.45 (-3.54%)

13:33
04/25/17
04/25
13:33
04/25/17
13:33
Hot Stocks
Buyout firm Encore sells snack maker Thanasi Foods to Conagra »

Private equity firm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHS

Universal Health

$121.38

0.48 (0.40%)

13:31
04/25/17
04/25
13:31
04/25/17
13:31
Technical Analysis
Universal Health technical notes ahead of earnings, potential bullish pattern »

On the weekly chart there…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.